JP7123339B2 - 銅に関連した疾患を処置するための手段及び方法 - Google Patents

銅に関連した疾患を処置するための手段及び方法 Download PDF

Info

Publication number
JP7123339B2
JP7123339B2 JP2018531559A JP2018531559A JP7123339B2 JP 7123339 B2 JP7123339 B2 JP 7123339B2 JP 2018531559 A JP2018531559 A JP 2018531559A JP 2018531559 A JP2018531559 A JP 2018531559A JP 7123339 B2 JP7123339 B2 JP 7123339B2
Authority
JP
Japan
Prior art keywords
methanobactin
copper
treatment
disease
medicament
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018531559A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018538306A (ja
JP2018538306A5 (enExample
Inventor
ツィシュカ，ハンス
リヒトマンネガー，ヨーゼフ
ディスピリト，アラン・アンジェロ
セムラウ，ジェレミー・デイヴィッド
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Iowa State University Research Foundation Inc
Original Assignee
Iowa State University Research Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Iowa State University Research Foundation Inc filed Critical Iowa State University Research Foundation Inc
Publication of JP2018538306A publication Critical patent/JP2018538306A/ja
Publication of JP2018538306A5 publication Critical patent/JP2018538306A5/ja
Application granted granted Critical
Publication of JP7123339B2 publication Critical patent/JP7123339B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/30—Copper compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/315—Zinc compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2018531559A 2015-12-18 2016-12-16 銅に関連した疾患を処置するための手段及び方法 Active JP7123339B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP15201070.8 2015-12-18
EP15201070 2015-12-18
LU92979 2016-02-19
LU92979 2016-02-19
PCT/EP2016/081407 WO2017103094A2 (en) 2015-12-18 2016-12-16 Means and methods for treating copper-related diseases

Publications (3)

Publication Number Publication Date
JP2018538306A JP2018538306A (ja) 2018-12-27
JP2018538306A5 JP2018538306A5 (enExample) 2020-01-23
JP7123339B2 true JP7123339B2 (ja) 2022-08-23

Family

ID=57758583

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018531559A Active JP7123339B2 (ja) 2015-12-18 2016-12-16 銅に関連した疾患を処置するための手段及び方法

Country Status (5)

Country Link
US (2) US11000568B2 (enExample)
EP (2) EP3389648A2 (enExample)
JP (1) JP7123339B2 (enExample)
CN (1) CN108472281B (enExample)
WO (1) WO2017103094A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108472281B (zh) * 2015-12-18 2023-09-08 德国亥姆霍兹慕尼黑中心健康与环境研究中心（有限公司） 用于治疗铜相关疾病的手段和方法
CN111094547B (zh) * 2017-06-14 2024-02-09 德国亥姆霍兹慕尼黑中心健康与环境研究中心（有限公司） 用于纯化源自人胚胎干细胞的内胚层和胰腺内胚层细胞的方法
CN109576226A (zh) * 2018-12-24 2019-04-05 博尔赛(上海)细胞生物技术有限公司 一种iPS细胞及其重编程方法和用途
CN109706099A (zh) * 2019-01-25 2019-05-03 黑龙江大学 同时去除低温地下水中有机磷农药和硝酸盐的假单胞菌及其应用
WO2021149824A1 (ja) * 2020-01-24 2021-07-29 アイ ピース， インコーポレイテッド 人工多能性幹細胞の作製方法
JP2022104813A (ja) 2020-12-29 2022-07-11 アイ ピース，インコーポレイテッド リプログラミング因子を導入された細胞の培養方法
JP2024504494A (ja) * 2021-02-01 2024-01-31 ヘルムホルツ・ツェントルム・ミュンヘン・ドイチェス・フォーシュンクスツェントルム・フュア・ゲズントハイト・ウント・ウンベルト・ゲーエムベーハー 鉄関連疾患の処置のためのメタノバクチンの使用
WO2025110984A1 (en) * 2023-11-21 2025-05-30 Hydrogene Therapeutics, Inc. Compositions and methods for treating wilson's disease
WO2026024138A1 (en) * 2024-07-25 2026-01-29 Arbormed Co., Ltd. Method for purifying methanobactin and methanobactin purified thereby

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004056849A2 (en) * 2002-12-19 2004-07-08 The University Of Kansas Methanobactin: a copper binding compound having antibiotic and antioxidant activity isolated from methanotrophic bacteria
US7932052B1 (en) * 2006-07-24 2011-04-26 The Regents Of The University Of Michigan Use of methanobactin
CN108472281B (zh) * 2015-12-18 2023-09-08 德国亥姆霍兹慕尼黑中心健康与环境研究中心（有限公司） 用于治疗铜相关疾病的手段和方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ACS Chem. Biol., (2012), 7, [2], p.260-268
J. Trace Elem. Med. Biol., (2011), 25, [1], p.36-41

Also Published As

Publication number Publication date
CN108472281B (zh) 2023-09-08
CA3000792A1 (en) 2017-06-22
US11000568B2 (en) 2021-05-11
WO2017103094A3 (en) 2017-07-27
JP2018538306A (ja) 2018-12-27
US20190328835A1 (en) 2019-10-31
EP4574207A2 (en) 2025-06-25
WO2017103094A2 (en) 2017-06-22
CN108472281A (zh) 2018-08-31
EP3389648A2 (en) 2018-10-24
EP4574207A3 (en) 2025-09-10
US20210369809A1 (en) 2021-12-02

Similar Documents

Publication Publication Date Title
US20210369809A1 (en) Means and methods for treating copper-related diseases
Glushchenko et al. Molecular targeting of proteins by L-homocysteine: mechanistic implications for vascular disease
US20230414709A1 (en) Mutant ngal proteins and uses thereof
Mori et al. Protein carbamylation exacerbates vascular calcification
Cho et al. The antimicrobial peptide arenicin-1 promotes generation of reactive oxygen species and induction of apoptosis
US12173037B1 (en) Mutant NGAL proteins and uses thereof
JP7290340B2 (ja) クロトータンパク質レベルを評価および改善するための製品および方法
Oppedisano et al. Inactivation by Hg2+ and methylmercury of the glutamine/amino acid transporter (ASCT2) reconstituted in liposomes: Prediction of the involvement of a CXXC motif by homology modelling
US9770500B2 (en) S-nitrosylation of glucosylating toxins and uses therefor
TWI592419B (zh) 製造具有氧化還原活性之低金屬化金屬硫蛋白的方法及含彼之醫藥組合物
CA3000792C (en) Means and methods for treating copper-related diseases
US20230165934A1 (en) Means and methods for treating copper-related diseases
US20240016772A1 (en) Compositions And Methods Comprising D-Cysteine Or A D-Derivative Thereof
Shafer From Chlamydomonas reinhardtii to Caenorhabditis elegans: Investigations into the Environmental Regulation of Eukaryotic Cu-Handling Mechanisms
Martelli Vascular effects of p-carboxyphenyl-isothiocyanate, a novel H2S-donor
Leitzinger Mitochondrial copper overload in a rat model for Wilson disease is paralleled by upregulated COX17 and can be restored using the bacterial peptide methanobactin
JP2024509996A (ja) Ｔｒｅｍ２に特異的な二環式ペプチドリガンド
Zaki et al. Formation of 8-nitroguanosine 3', 5'-cyclic monophosphate and its involvement in NO-mediated host defense during salmonellosis
Jiang et al. Enhanced Binding Strength of Aggregated Amyloid-β Enables Its Copper Sequestration from Albumin: a Pathway to Accumulation of Copper in Senile Plaques

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191203

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191203

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20201023

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201104

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210118

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210608

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210906

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211108

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220405

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220426

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220705

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220801

R150 Certificate of patent or registration of utility model

Ref document number: 7123339

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250